Ledipasvir + GS-9451+peginterferon and ribavrin (PR) for six or 12 weeks achieves a high SVR12 in treatment naive genotype 1 IL28B CC patients

被引：0
|
作者：
Thompson, A. [1 ]
Shiffman, M. [2 ]
Pianko, S. [3 ]
Kanwar, B. [4 ]
Mchutchison, J. [4 ]
Muir, A. J. [5 ]
Lee, S. [6 ]
George, J. [7 ]
机构：
[1] St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[2] Liver Inst Virginia, Norfolk, VA USA
[3] Monash Med Ctr, Clayton, Vic 3168, Australia
[4] Gilead Sci Inc, Foster City, CA 94404 USA
[5] Duke Clin Res Inst, Durham, NC USA
[6] Univ Calgary, Calgary, AB, Canada
[7] Westmead Hosp, Westmead, NSW 2145, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 26 条
  • [21] Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area
    Chung, Hyun Jung
    Lee, Jin-Woo
    Kim, Young Soo
    Lee, Jung Il
    INTERVIROLOGY, 2013, 56 (03) : 178 - 183
  • [22] A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naive Patients and 93% in Prior Null Responders with HCV Genotype1 Infection
    Kowdley, Kris V.
    Lawitz, Eric
    Poordad, Fred
    Cohen, Daniel E.
    Nelson, David R.
    Zeuzem, Stefan
    Everson, Gregory T.
    Kwo, Paul Y.
    Foster, Graham R.
    Sulkowski, Mark S.
    Xie, Wangang
    Pilot-Matias, Tami
    Liossis, George
    Larsen, Lois M.
    Khatri, Amit
    Podsadecki, Thomas J.
    Bernstein, Barry
    HEPATOLOGY, 2012, 56 (06) : 1515 - 1516
  • [23] HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS
    Sulkowski, M.
    Rodriguez-Torres, M.
    Lawitz, E.
    Shiffman, M.
    Pol, S.
    Herring, R.
    McHutchison, J.
    Pang, P.
    Brainard, D.
    Wyles, D.
    Habersetzer, F.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S560 - S560
  • [24] A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS
    Lawitz, E.
    Poordad, F.
    Kowdley, K. V.
    Jensen, D.
    Cohen, D. E.
    Siggelkow, S.
    Wikstrom, K.
    Larsen, L.
    Menon, R. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S7 - S7
  • [25] HIGH SUSTAINED VIRAL RESPONSE AT 12-AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS
    Manns, M.
    Vierling, J. M.
    Bacon, B. R.
    Marcellin, P.
    Caro, L.
    Gress, J.
    Gilbert, C.
    Cooreman, M. P.
    Robertson, M.
    Hwang, P.
    Wahl, J.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S30 - S30
  • [26] PEGYLATED INTERFERON LAMBDA (PEG-IFN-λ) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12
    Muir, Andrew J.
    Lawitz, Eric
    Ghalib, Reem H.
    Sussman, Norman L.
    Anderson, Frank
    Everson, Gregory T.
    Jacobson, Ira M.
    Lopez-Talavera, Juan Carlos
    Hillson, Jan L.
    Gray, Todd E.
    Fontana, David
    Ramos, Eleanor L.
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2010, 52 (04) : 715A - 716A
123